New drugs and patient-centred end-points in old age: setting the wheels in motion

Arduino Mangoni, Alberto Pilotto

    Research output: Contribution to journalArticlepeer-review

    7 Citations (Scopus)


    Older patients with various degrees of frailty and disability, a key population target of pharmacological interventions in acute and chronic disease states, are virtually neglected in pre-marketing studies assessing the efficacy and safety of investigational drugs. Moreover, aggressively pursuing established therapeutic targets in old age, e.g. blood pressure, serum glucose or cholesterol concentrations, is not necessarily associated with the beneficial effects, and the acceptable safety, reported in younger patient cohorts. Measures of self-reported health and functional status might represent additional, more meaningful, therapeutic end-points in the older population, particularly in patients with significant frailty and relatively short life expectancy, e.g. in the presence of cancer and/or neurodegenerative disease conditions. Strategies enhancing early knowledge about key pharmacological characteristics of investigational drugs targeting older adults are discussed, together with the rationale for incorporating non-traditional, patient-centred, end-points in this ever-increasing group.

    Original languageEnglish
    Pages (from-to)81-89
    Number of pages9
    JournalExpert Review of Clinical Pharmacology
    Issue number1
    Publication statusPublished - 2 Jan 2016


    • drug development
    • efficacy
    • frailty
    • functional status
    • older adults
    • pharmacodynamics
    • pharmacokinetics
    • safety
    • therapeutic goals


    Dive into the research topics of 'New drugs and patient-centred end-points in old age: setting the wheels in motion'. Together they form a unique fingerprint.

    Cite this